Sites of infections among the first hospital stay with a discharge diagnosis of infection within 6 months after rituximab in adult patients with incident primary AIHA
| Sites of infections, n (%) . | Total . | Age groups . | Sex . | Corticosteroids . | |||
|---|---|---|---|---|---|---|---|
| 18-69 y . | ≥70 y . | Female . | Male . | Exposed∗ . | Not exposed . | ||
| Total | 169 (100.0) | 43 (100.0) | 126 (100.0) | 99 (100.0) | 70 (100.0) | 112 (100.0) | 57 (100.0) |
| Pulmonary | 68 (40.2) | 14 (32.6) | 54 (42.9) | 35 (35.4) | 33 (47.1) | 50 (44.6) | 18 (31.6) |
| Urogenital | 27 (16.0) | 4 (9.3) | 23 (18.3) | 23 (23.2) | 4 (5.7) | 19 (17.0) | 8 (14.0) |
| Gastrointestinal | 21 (12.4) | 6 (14.0) | 15 (11.9) | 11 (11.1) | 10 (14.3) | 13 (11.6) | 8 (14.0) |
| Dermatological | 13 (7.7) | 6 (14.0) | 7 (5.6) | 8 (8.1) | 5 (7.1) | 9 (8.0) | 4 (7.0) |
| Equipment | 4 (2.4) | 1 (2.3) | 3 (2.4) | 2 (2.0) | 2 (2.9) | 3 (2.7) | 1 (1.8) |
| Cardiovascular | 3 (1.8) | 1 (2.3) | 2 (1.6) | 1 (1.0) | 2 (2.9) | 1 (0.9) | 2 (3.5) |
| Musculoskeletal | 2 (1.2) | 1 (2.3) | 1 (0.8) | 2 (2.0) | 0 (0.0) | 0 (0.0) | 2 (3.5) |
| Upper respiratory tract | 2 (1.2) | 0 (0.0) | 2 (1.6) | 1 (1.0) | 1 (1.4) | 1 (0.9) | 1 (1.8) |
| Nervous system | 1 (0.6) | 0 (0.0) | 1 (0.8) | 1 (1.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Unspecified site† | 34 (20.1) | 10 (23.3) | 24 (19.0) | 20 (20.2) | 14 (20.0) | 21 (18.8) | 13 (22.8) |
| Sites of infections, n (%) . | Total . | Age groups . | Sex . | Corticosteroids . | |||
|---|---|---|---|---|---|---|---|
| 18-69 y . | ≥70 y . | Female . | Male . | Exposed∗ . | Not exposed . | ||
| Total | 169 (100.0) | 43 (100.0) | 126 (100.0) | 99 (100.0) | 70 (100.0) | 112 (100.0) | 57 (100.0) |
| Pulmonary | 68 (40.2) | 14 (32.6) | 54 (42.9) | 35 (35.4) | 33 (47.1) | 50 (44.6) | 18 (31.6) |
| Urogenital | 27 (16.0) | 4 (9.3) | 23 (18.3) | 23 (23.2) | 4 (5.7) | 19 (17.0) | 8 (14.0) |
| Gastrointestinal | 21 (12.4) | 6 (14.0) | 15 (11.9) | 11 (11.1) | 10 (14.3) | 13 (11.6) | 8 (14.0) |
| Dermatological | 13 (7.7) | 6 (14.0) | 7 (5.6) | 8 (8.1) | 5 (7.1) | 9 (8.0) | 4 (7.0) |
| Equipment | 4 (2.4) | 1 (2.3) | 3 (2.4) | 2 (2.0) | 2 (2.9) | 3 (2.7) | 1 (1.8) |
| Cardiovascular | 3 (1.8) | 1 (2.3) | 2 (1.6) | 1 (1.0) | 2 (2.9) | 1 (0.9) | 2 (3.5) |
| Musculoskeletal | 2 (1.2) | 1 (2.3) | 1 (0.8) | 2 (2.0) | 0 (0.0) | 0 (0.0) | 2 (3.5) |
| Upper respiratory tract | 2 (1.2) | 0 (0.0) | 2 (1.6) | 1 (1.0) | 1 (1.4) | 1 (0.9) | 1 (1.8) |
| Nervous system | 1 (0.6) | 0 (0.0) | 1 (0.8) | 1 (1.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
| Unspecified site† | 34 (20.1) | 10 (23.3) | 24 (19.0) | 20 (20.2) | 14 (20.0) | 21 (18.8) | 13 (22.8) |